Literature DB >> 15968099

Identification of clonotypic IgH VDJ sequences in multiple myeloma.

Brian J Taylor1, Jitra Kriangkum, Erin R Strachan, Juanita Wizniak, Linda M Pilarski.   

Abstract

In multiple myeloma (MM) the rearranged immunoglobulin heavy chain (IgH) variable, diversity, and joining (VDJ) DNA sequence of malignant plasma cells (PCs) serves as a marker for cells in the MM clone. This clonotypic sequence can be isolated from MM PCs by reverse transcriptase polymerase chain reaction (RT-PCR) with consensus primers that amplify the rearranged IgH repertoire. This chapter focuses on the key steps in determining patient-specific clonotypic sequences, including bulk RT-PCR using purified bone marrow mononuclear cell (BMMC) RNA, single-cell RT-PCR using RNA from PCs sorted by flow cytometry, IgH sequence alignments using IMGT or V BASE, and patient-specific primer design. In a test panel of several MM patient BMMCs, primers specific for the proposed sequence must amplify IgH from only the original patient. Furthermore, the proposed IgH sequence is not confirmed as clonotypic until these primers generate positive amplifications in the majority of single PCs from the original patient. This two-part test ensures that the proposed IgH sequence satisfies the definition of the clonotypic sequence as the most frequent, unique IgH sequence in an MM patient PC sample. With this patient-specific MM marker, a better understanding of transformed PCs and their B-lineage predecessors can be developed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968099     DOI: 10.1385/1-59259-916-8:121

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  3 in total

1.  Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia.

Authors:  Jitra Kriangkum; Sarah N Motz; Tanner Mack; Sara Beiggi; Eva Baigorri; Hemalatha Kuppusamy; Andrew R Belch; James B Johnston; Linda M Pilarski
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

2.  In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Authors:  Kyle J Thulien; Andrew R Belch; Tony Reiman; Linda M Pilarski
Journal:  Mol Cancer       Date:  2012-10-19       Impact factor: 27.401

3.  Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.

Authors:  Jitra Kriangkum; Sarah N Motz; Carina S Debes Marun; Sandrine T Lafarge; Spencer B Gibson; Christopher P Venner; James B Johnston; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.